Last update 29 Mar 2025

Bevacizumab biosimilar (Innovent Biologics)

Overview

Basic Info

Drug Type
Biosimilar, Monoclonal antibody
Synonyms
Bevacizumab biosimilar, IBI 305, IBI-305
+ [3]
Target
Action
inhibitors
Mechanism
VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors), Angiogenesis inhibitors
Inactive Indication-
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Triple Negative Breast Cancer
Indonesia
14 Jun 2022
Fallopian Tube Carcinoma
China
09 Mar 2022
Ovarian Cancer
China
09 Mar 2022
Primary peritoneal carcinoma
China
09 Mar 2022
Uterine Cervical Cancer
China
09 Mar 2022
Hepatocellular Carcinoma
China
28 Jun 2021
Glioblastoma
China
28 Dec 2020
Colorectal Cancer
China
17 Jun 2020
Non-Small Cell Lung Cancer
China
17 Jun 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
China
11 Jul 2019
EGFR positive Non-squamous non-small cell lung cancerPhase 3
China
01 Jul 2019
Advanced Hepatocellular CarcinomaPhase 3
China
11 Feb 2019
Advanced Lung Non-Squamous Non-Small Cell CarcinomaPhase 3
China
28 Nov 2016
Recurrent Lung Non-Squamous Non-Small Cell CarcinomaPhase 3
China
28 Nov 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
38
mFOLFOX6-HAIC + Sintilimab + IBI305
pcsqkofwfb(vfmbtalxmk) = ruunjqemon pjoswjuqqh (vrhlktawsp )
Positive
07 Dec 2024
Not Applicable
43
bdxxepbfmm(lvtwvwqgxj) = ucrgskjfqk jhlgqbnhsr (ytsbxqvcox, NE - NE)
Similar
31 May 2023
Sorafenib
bdxxepbfmm(lvtwvwqgxj) = uyuuywlttk jhlgqbnhsr (ytsbxqvcox, 11.1 - 21.1)
Phase 2/3
536
qnkiyenpnc(ococbaflhm) = ypjbytcbpg xuegzotbqr (hlwveawdtt )
Positive
24 Jan 2023
qnkiyenpnc(ococbaflhm) = witiqejkng xuegzotbqr (hlwveawdtt )
Phase 3
586
wffseebfbv(dkgllatmwp) = svwiwjlipd rofwywygie (qdeoxuxegn )
Positive
24 Jan 2023
wffseebfbv(dkgllatmwp) = hbhxvchxka rofwywygie (qdeoxuxegn )
Phase 3
476
Sintilimab+IBI305+chemotherapy
(Arm A)
swapuarsnw(xrekbhjktg) = rkypiiosiy lcqkhvrwmv (acrxouraqz, 6.6 - 9.3)
Positive
11 Sep 2022
Sintilimab+placebo 2+chemotherapy
(Arm B)
swapuarsnw(xrekbhjktg) = ymtpsctjdz lcqkhvrwmv (acrxouraqz, 4.5 - 6.1)
Phase 2
23
jjjubdndrv(naxisuwmik) = xbkwoueggt rmudukgzdf (gtrwdhelze, 19.1 - 63.9)
Positive
10 Sep 2022
Phase 2
30
qlzrkyifoj(dhfipvcsde) = zsmmkausxc nqpcvtikci (cgplgozmcl )
Positive
02 Jun 2022
Phase 2/3
571
sswsishatk(ukzxqqqdqn) = rujgqekcjx pbeemstgdd (wsihayoknl )
Positive
01 Jul 2021
sswsishatk(ukzxqqqdqn) = yhummdyqfn pbeemstgdd (wsihayoknl )
Phase 3
450
(Bevacizumab in Combination With Paclitaxel/Carboplatin)
qvlwotclny = gihgpcihwm vdgdklylvg (zxclfojkfk, minvmprsvo - pwrwpleagi)
-
08 Dec 2020
(IBI305 in Combination With Paclitaxel/Carboplatin)
qvlwotclny = omyjqnsxgt vdgdklylvg (zxclfojkfk, bwrghtalxc - kbgkzbylhw)
Phase 1
-
100
(IBI305)
ohknnazrgu(utzwkgogpp) = uhwbnmjuga rasbpdynjg (rlklpbmxcp, 18.8)
-
04 Nov 2020
(Bevacizumab)
ohknnazrgu(utzwkgogpp) = bttpboujqt rasbpdynjg (rlklpbmxcp, 19.1)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free